Gene · 369
NIH grants1,471
NIH grants whose papers are about the gene, through NIH's grant-paper links.
521 to 540 of 1,471
Download this page as JSON| Grant | Title | ARAF papers | Newest fiscal year |
|---|---|---|---|
| F32CA243290 | Elucidating the role of SHOC2 to enhance MEK inhibitor sensitivity in pancreatic cancer | 1 | 2021 |
| F32CA254070 | Investigating concurrent Ras-pathway inhibition to optimize response to anti-PD-1 therapy in NRAS-mutant melanoma | 1 | 2021 |
| K08CA204732 | Mechanistic Dissection of an Arginine Methyltransferase Dependency in Cancer | 1 | 2021 |
| K08HL135434 | Targeting SETBP1 in Myeloproliferative Disorders | 1 | 2021 |
| K22CA216008 | G0S2 in chronic myeloid leukemia disease progression and imatinib resistance | 1 | 2021 |
| P01NS099114 | Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways | 1 | 2021 |
| P20GM119943 | Stem Cells and Aging | 1 | 2021 |
| P30MH062261 | Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center | 1 | 2021 |
| P50CA217685 | U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer | 1 | 2021 |
| R01AG057907 | Integrative Network Modeling of Cognitive Resilience to Alzheimer's Disease | 1 | 2021 |
| R01AG057912 | Molecular Networks Underlying Resilience to Alzheimer's Disease Among APOE E4 Carriers | 1 | 2021 |
| R01CA136533 | Deciphering the Code for Senescence Escape During Cancer Progression in Humans | 1 | 2021 |
| R01CA160467 | Development of novel anti-leukemia agents targeting the menin-MLL interaction | 1 | 2021 |
| R01CA166480 | MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer | 1 | 2021 |
| R01CA188134 | Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response | 1 | 2021 |
| R01CA198128 | Exploiting Caveolae-Dependent Albumin Endocytosis to optimize Therapy in Pancreatic Cancer | 1 | 2021 |
| R01CA204481 | Guanylin GUCY2C axis in Colorectal Cancer Initiation | 1 | 2021 |
| R01CA206890 | Imaging tumor associated macrophage (TAM) function | 1 | 2021 |
| R01CA210509 | Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer | 1 | 2021 |
| R01CA213428 | Molecular studies of the MR-detectable oncometabolite glycerophosphocholine | 1 | 2021 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/grants?page=27